ClinicalTrials.gov
public full text
Public Domain
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies. This study is an open-labeled single-arm phase II diagnostic clinical trial to explore the clinical value of 68Ga-TCR-FAPI PET/CT in suspected malignant tumor patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Applications of FAPI PET in Solid Tumors#1261834
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers#1245066
- Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients#1282799
- 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma#1031880
- [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer#846033
Record · ID 1409251
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive